ESC 2019 Prof. John Kastelein shares the results of the phase 3 ORION-11 trial with inclisiran in ASCVD and risk equivalent patients not at LDL-C goal.
This video was recorded at ESC 2019 in Paris, France, on September 2, 2019.
Prof. John Kastelein, MD – Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascular Disease.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Camilla Bang, MD
Prof. François Mach, MD
Prof. Freek Verheugt